Stents, scaffolds and DCB

Explore this session to discover innovative approaches to the management of complex coronary aneurysms. From contrast-induced nephropathy prevention using a balloon angiography system to rescue techniques for wire fracture during atherectomy, you'll gain insights into navigating challenging scenarios. Dive deeper into the percutaneous exclusion of a...

Join us for this dynamic 'Best Abstracts' session, where we delve into the latest research and insights from the world of interventional cardiology. Explore a diverse range of topics, from the use of E/e ratio as a marker for predicting periprocedural myocardial infarction in diabetic patients,...

Explore the future of complex PCI with Meril Life’s advanced solutions. Learn about thin-strut platforms, dedicated stents for side branches and diffuse lesions, the role of drug-eluting balloons in metal-free PCI, and the clinical potential of the Myval THV technology.

DCBs have undergone extensive development to meet the challenges of minimizing restenosis and maintaining vessel patency. Unlike stents, DCBs deliver an antiproliferative drug directly to the arterial wall without leaving a permanent implant. This approach has proven effective in treating small-vessel disease, in-stent restenosis, and de...

The present study compares a novel sirolimus-coated balloon with a clinically proven paclitaxel-coated balloon for the treatment of de novo coronary lesions, demonstrating non-inferiority in terms of angiographic late lumen loss at 6 months.

The purpose of this case report is to discuss the treatment of a chronic total occlusion (CTO) in a 58-year-old male patient with multiple cardiovascular risk factors including type 2 diabetes, dyslipidemia, hypertension, and smoking history.

Angio showed a CTO of the RCA. In the MR-Scan, the RCA...

Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

A 73-year-old male with complex recurrent in-stent restenosis of the left main underwent an innovative treatment approach. Six-month follow-up revealed remarkable recovery and positive remodelling. Discover how Piotr Buszman and Mateusz Kachel tackled this challenging case.

Drug-coated balloon (DCB) angioplasty has become a valuable alternative to drug-eluting stents in treating coronary artery disease. To achieve optimal outcomes, proper lesion preparation and techniques to minimise drug loss are crucial.

This article highlights key steps and best practices for performing DCB angioplasty, ensuring effective drug delivery and...

Authored by Hector Garcia-Garcia and Jorge Sanz-Sanchez, this article examines pivotal randomized clinical trials on drug-coated balloons in coronary artery disease. It highlights their role in managing in-stent restenosis, de novo small vessel lesions, and large vessel lesions while exploring future directions through ongoing trials.